Molecure S.A. (WSE:MOC)
5.31
-0.09 (-1.67%)
Nov 4, 2026, 3:00 PM CET
Molecure Revenue
Molecure had revenue of 825.24K PLN in the quarter ending September 30, 2026, with 156.13% growth. This brings the company's total for the last twelve months to 5.28M, down -7.89% year-over-year. In the year 2025, Molecure had annual revenue of 6.52M with 122.20% growth. That makes Molecure the 42,751st largest company in the world by revenue and 456th in Poland.
Revenue (ttm)
5.28M
Revenue Growth
-7.89%
P/S Ratio
17.07
Revenue / Employee
91.82K
Employees
71
Market Cap
109.40M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.52M | 3.59M | 122.20% |
| Dec 31, 2024 | 2.93M | -738.15K | -20.10% |
| Dec 31, 2023 | 3.67M | -3.87M | -51.29% |
| Dec 31, 2022 | 7.54M | 6.08M | 416.21% |
| Dec 31, 2021 | 1.46M | -123.45M | -98.83% |
| Dec 31, 2020 | 124.91M | 122.88M | 6,039.22% |
| Dec 31, 2019 | 2.03M | 626.09K | 44.45% |
| Dec 31, 2018 | 1.41M | -63.01K | -4.28% |
| Dec 31, 2017 | 1.47M | -146.99K | -9.08% |
| Dec 31, 2016 | 1.62M | 612.55K | 60.89% |
| Dec 31, 2015 | 1.01M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BIOTON | 257.23M |
| Ryvu Therapeutics | 83.94M |
| Synthaverse | 48.76M |
| Mabion | 17.61M |
| Read-Gene | 16.66M |
| Urteste | 2.77M |
| NanoGroup | 2.37M |
| Captor Therapeutics Spolka Akcyjna | 2.01M |
Molecure News
- 4 days ago - Molecure Quarterly report: Q3 2026 - Filings
- 4 weeks ago - Molecure Quarterly report: Q2 2026 - Filings
- 5 months ago - Molecure Quarterly report: Q1 2026 - Filings
- 7 months ago - Molecure Annual report: Q4 2025 - Filings